Loading patent…
AssigneesTechnophage, InvestigaçãO E Desenvolvimento Em Biotecnologia, SA, FundaçäO Gimm—Gulbenkian Institute for Molecular Medicine
InventorsDiana Sofia Chapela Duarte Pires, Sofia Marisa Volker Côrte-Real, Maria Leonor Tavares Saúde, Isaura Vanessa Antunes Martins, Sara Cristina Mauricio De Sousa
Estimating the term…
The present invention discloses the use of Eletriptan Hydrobromide in the treatment of spinal cord injury and improvement of the locomotive function. Despite the major efforts done in attempting to improve the limited recovery upon injury, only a multi-target combinatorial therapeutic approach should be effective for the complexity of spinal cord injury nature. Taking advantage of a larval zebrafish drug discovery platform it is identified herein that Eletriptan Hbr has locomotor recovery properties in a pro-regenerative model and it has been confirmed to have conservative effect on a rodent (pro-fibrotic) contusion model. This approach allowed to identify a promising new therapeutic indication for Eletriptan Hbr, which associated with a combinatorial therapeutic strategy and innovative engineering approaches, shows great potential for spinal cord injury recovery.
A method of treating spinal cord injury comprising a contusion in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Eletriptan Hydrobromide or a pharmaceutical composition thereof.
A method of protecting from microvascular leakage in a spinal cord tissue of a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Eletriptan Hydrobromide or a pharmaceutical composition thereof.
Dependencies are inferred from the claim text.